Payment overview · 2025
General Payments
$85.24
3 reported records · 2 companies
Healthcare provider profile · identity verified
Michael L. Peck, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PLYMOUTH MEETING, PA · NPI 1265427306
Verified facts
What the public records show
CMS Open Payments records show Michael L. Peck, D.O. received $85.24 in general payments during 2025 across 3 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 82.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $69.96 | 82.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.28 | 17.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $85.24 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $69.96 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1491 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1082 | 81 |
| Sertraline Hcl | Sertraline Hcl | 967 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 886 | 80 |
| Furosemide | Furosemide | 870 | 96 |
| Gabapentin | Gabapentin | 766 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 719 | 65 |
| Eliquis | Apixaban | 676 | 66 |
| Lisinopril | Lisinopril | 635 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 621 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 569 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 555 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 551 | 56 |
| Omeprazole | Omeprazole | 506 | 59 |
| Mirtazapine | Mirtazapine | 484 | 37 |
| Memantine Hcl | Memantine Hcl | 450 | 31 |
| Potassium Chloride | Potassium Chloride | 445 | 55 |
| Losartan Potassium | Losartan Potassium | 428 | 45 |
| Donepezil Hcl | Donepezil Hcl | 424 | 31 |
| Metformin Hcl | Metformin Hcl | 411 | 33 |
| Carvedilol | Carvedilol | 402 | 25 |
| Famotidine | Famotidine | 364 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 350 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 349 | 29 |
| Finasteride | Finasteride | 317 | 20 |
| Buspirone Hcl | Buspirone Hcl | 306 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 247 | 12 |
| Levetiracetam | Levetiracetam | 237 | 19 |
| Prednisone | Prednisone | 234 | 27 |
| Torsemide | Torsemide | 225 | 20 |
| Trazodone Hcl | Trazodone Hcl | 224 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 223 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 210 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 19 |
| Risperidone | Risperidone | 170 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 166 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 159 | 16 |
| Baclofen | Baclofen | 158 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 146 | 16 |
| Spironolactone | Spironolactone | 144 | 21 |
| Xarelto | Rivaroxaban | 144 | 12 |
| Jardiance | Empagliflozin | 143 | 13 |
| Allopurinol | Allopurinol | 139 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 138 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 13 |
| Aripiprazole | Aripiprazole | 123 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 123 | 12 |
| Bumetanide | Bumetanide | 120 | 12 |
| Glimepiride | Glimepiride | 120 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 119 | 13 |
| Montelukast Sodium | Montelukast Sodium | 119 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 116 | 14 |
| Januvia | Sitagliptin Phosphate | 116 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 113 | suppressed |
| Simvastatin | Simvastatin | 113 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 107 | 107 |
| Myrbetriq | Mirabegron | 104 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 15 |
| Latanoprost | Latanoprost | 93 | 18 |
| Atenolol | Atenolol | 87 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 86 | 35 |
| Dicyclomine Hcl | Dicyclomine Hcl | 85 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 83 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 30 |
| Warfarin Sodium | Warfarin Sodium | 78 | 15 |
| Lovastatin | Lovastatin | 76 | suppressed |
| Nifedipine Er | Nifedipine | 73 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 68 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 65 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 25 |
| Tramadol Hcl | Tramadol Hcl | 64 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | suppressed |
| Olanzapine | Olanzapine | 62 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 61 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 59 | suppressed |
| Calcitriol | Calcitriol | 59 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 59 | suppressed |
| Entresto | Sacubitril/Valsartan | 57 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 54 | 16 |
| Budesonide | Budesonide | 54 | suppressed |
| Trulicity | Dulaglutide | 54 | 11 |
| Carbamazepine Er | Carbamazepine | 52 | suppressed |
| Lorazepam | Lorazepam | 52 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 52 | suppressed |
| Amantadine | Amantadine Hcl | 50 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 29 |
| Trospium Chloride Er | Trospium Chloride | 50 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 49 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 18 |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Lansoprazole | Lansoprazole | 45 | suppressed |
| Meloxicam | Meloxicam | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Sotalol | Sotalol Hcl | 42 | suppressed |
| Levemir Flexpen | Insulin Detemir | 40 | suppressed |
| Methotrexate | Methotrexate Sodium | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Metolazone | Metolazone | 36 | suppressed |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Nyamyc | Nystatin | 36 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Telmisartan | Telmisartan | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | 18 |
| Gemtesa | Vibegron | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 25 |
| Loperamide | Loperamide Hcl | 32 | 16 |
| Dutasteride | Dutasteride | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 30 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Nystatin | Nystatin | 30 | 15 |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 28 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 27 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 20 |
| Lidocaine Hcl | Lidocaine Hcl | 26 | 20 |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 24 | 16 |
| Morphine Sulfate | Morphine Sulfate | 24 | 14 |
| Primidone | Primidone | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 14 |
| Glipizide | Glipizide | 23 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 13 |
| Cefuroxime | Cefuroxime Axetil | 20 | 16 |
| Diazepam | Diazepam | 20 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Mirabegron Er | Mirabegron | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Cholestyramine Light | Cholestyramine | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Latuda | Lurasidone Hcl | 17 | suppressed |
| Methazolamide | Methazolamide | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 14 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 13 | 13 |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | 12 |
| Alprazolam | Alprazolam | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Dronabinol | Dronabinol | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Procrit | Epoetin Alfa | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $85.24 · 3 records | Otsuka America Pharmaceutical, Inc. | Ozempic, REXULTI, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error